Streetbeat News

Regulatory

CS

UBS

Credit Suisse (NYSE:CS) has scrapped plans to set up a locally incorporated bank in China due to potential regulatory conflicts arising from its merger with UBS Group (NYSE:UBS). The move could impact the banks' ability to expand their onshore wealth management business and presence in China.

Portfolio Pulse from Akanksha Bakshi

May 31, 2023 | 12:31 pm

SPY

U.S. House Majority Whip Emmer announced that they will have the votes to pass the debt ceiling bill on Wednesday night, ensuring the government avoids default.

Portfolio Pulse from Happy Mohamed

May 31, 2023 | 12:30 pm

AAPL

GOOG

GOOGL

India's IT regulator plans to certify permissible online games until the gaming industry establishes a self-regulatory organization (SRO). Apple and Google will be notified to ensure compliance with the certification process. Apple has not refused to comply with the February order to ban 138 betting apps but requires a concrete reason or legal requirement to remove them.

Portfolio Pulse from Arpit Nayak

May 31, 2023 | 12:21 pm

ARDS

Aridis Pharmaceuticals announced that it has received FDA agreement for its proposed single confirmatory Phase 3 study of AR-301 and the clinical study design, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 12:20 pm

HZNP

Horizon Therapeutics announced new results from its Phase 2 trial evaluating Dazodalibep in Sjögren's Syndrome at the 2023 EULAR European Congress of Rheumatology. The results show promise for the treatment of this autoimmune disease.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 12:19 pm

ITCI

Intra-Cellular Therapies (NASDAQ: ITCI) announced several CAPLYTA data presentations at the American Society of Clinical Psychopharmacology Annual Meeting. The presentations provide information about CAPLYTA's efficacy, safety, and tolerability profile in treating bipolar I and II depression.

Portfolio Pulse from Happy Mohamed

May 31, 2023 | 12:08 pm

PGEN

Precigen has received FDA clearance to initiate a Phase 2 study of PRGN-2009, an off-the-shelf AdenoVerse immunotherapy, in combination with pembrolizumab for the treatment of recurrent or metastatic cervical cancer.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 12:06 pm

CLDX

Celldex Therapeutics has announced the dosing of the first patient in a Phase 1 clinical trial of CDX-585, a treatment for patients with advanced malignancies.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 12:06 pm

COCP

Cocrystal Pharma has received approval from the Human Research Ethics Committee (HREC) to initiate a Phase 1 study for its oral broad-spectrum coronavirus 3CL protease inhibitor, CDI-988. This marks a significant step in the development of a potential treatment for COVID-19.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 12:03 pm

ARDS

Aridis Pharmaceuticals has received agreement from the FDA for a single confirmatory Phase 3 study of AR-301 and its clinical study design. This will potentially expedite the development and approval process for the treatment.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 12:02 pm